Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices.
Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, van de Velde H, Niculescu L, Bonthapally V, Goy A. Skarbnik AP, et al. Among authors: niculescu l. Leuk Lymphoma. 2017 Aug;58(8):1968-1972. doi: 10.1080/10428194.2016.1272688. Epub 2017 Jan 16. Leuk Lymphoma. 2017. PMID: 28092998 No abstract available.
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.
Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV. Kumar SK, et al. Among authors: niculescu l. Leukemia. 2016 Apr;30(4):995-8. doi: 10.1038/leu.2015.225. Epub 2015 Aug 14. Leukemia. 2016. PMID: 26271606 No abstract available.
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA Jr, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG. Laubach JP, et al. Among authors: niculescu l. Br J Haematol. 2017 Aug;178(4):547-560. doi: 10.1111/bjh.14708. Epub 2017 May 3. Br J Haematol. 2017. PMID: 28466536 Free PMC article.
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
Mateos MV, Richardson PG, Dimopoulos MA, Palumbo A, Anderson KC, Shi H, Elliott J, Dow E, van de Velde H, Niculescu L, San Miguel JF. Mateos MV, et al. Among authors: niculescu l. Am J Hematol. 2015 Apr;90(4):314-9. doi: 10.1002/ajh.23933. Epub 2015 Feb 27. Am J Hematol. 2015. PMID: 25557740 Free article. Clinical Trial.
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J. Niesvizky R, et al. Among authors: niculescu l. J Clin Oncol. 2015 Nov 20;33(33):3921-9. doi: 10.1200/JCO.2014.58.7618. Epub 2015 Jun 8. J Clin Oncol. 2015. PMID: 26056177 Clinical Trial.
The challenge of cross-trial comparisons using limited data.
Laubach JP, Faber EA Jr, Voorhees P, Moslehi J, Varga C, Niculescu L, Anderson KC, Richardson PG. Laubach JP, et al. Among authors: niculescu l. Haematologica. 2014 Aug;99(8):e145-6. doi: 10.3324/haematol.2013.103135. Haematologica. 2014. PMID: 25082787 Free PMC article. No abstract available.
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.
Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, Motzer RJ. Ewer MS, et al. Among authors: niculescu l. Eur J Cancer. 2014 Aug;50(12):2162-70. doi: 10.1016/j.ejca.2014.05.013. Epub 2014 Jun 12. Eur J Cancer. 2014. PMID: 24930624
Long-term efficacy and safety of celecoxib in Alzheimer's disease.
Soininen H, West C, Robbins J, Niculescu L. Soininen H, et al. Among authors: niculescu l. Dement Geriatr Cogn Disord. 2007;23(1):8-21. doi: 10.1159/000096588. Epub 2006 Oct 26. Dement Geriatr Cogn Disord. 2007. PMID: 17068392 Clinical Trial.
62 results